Clinical Decision Support
Generate professional clinical decision support documents with GRADE evidence grading and statistical analysis for cardiology content.
Triggers
- User needs evidence-based treatment recommendations
- User is creating clinical guideline summaries
- User wants to analyze patient cohort data
- User needs to present evidence with GRADE grading
- User is developing clinical algorithms
Document Types
1. Treatment Recommendation Reports
Structure:
- Clinical question (PICO format)
- Evidence summary
- GRADE assessment
- Recommendation statement
- Implementation considerations
GRADE Evidence Levels:
| Grade |
Certainty |
Meaning |
| 1A |
High |
Strong recommendation, high-quality evidence |
| 1B |
Moderate |
Strong recommendation, moderate evidence |
| 2A |
High |
Weak recommendation, high-quality evidence |
| 2B |
Moderate |
Weak recommendation, moderate evidence |
| 2C |
Low |
Weak recommendation, low-quality evidence |
2. Patient Cohort Analysis
Components:
- Demographics and baseline characteristics
- Biomarker stratification
- Outcome comparisons with statistics
- Subgroup analyses
- Clinical implications
3. Guideline Summaries
Elements:
- Recommendation class (I, IIa, IIb, III)
- Level of evidence (A, B, C)
- Key supporting trials
- Clinical context
- Special populations
Cardiology-Specific Applications
Heart Failure Management
- GDMT optimization pathways
- Device therapy eligibility
- Risk stratification (MAGGIC, Seattle HF Model)
- Stage-based recommendations
Coronary Artery Disease
- Revascularization decisions
- Medical therapy optimization
- Risk scores (SYNTAX, HEART, TIMI)
- Secondary prevention
Arrhythmia Management
- Anticoagulation decisions (CHA₂DS₂-VASc)
- Rate vs rhythm control
- Device therapy indications
- Ablation candidacy
Valvular Heart Disease
- Intervention timing
- Surgical vs transcatheter approach
- Risk assessment (STS, EuroSCORE)
- Surveillance recommendations
Statistical Presentation
Required Elements
- Hazard ratios with 95% CI
- Absolute risk differences
- Number needed to treat (NNT)
- P-values (exact, not just thresholds)
- Forest plots for multiple comparisons
Survival Analysis Display
- Kaplan-Meier curves
- Number at risk tables
- Median survival with CI
- Landmark analyses if appropriate
Evidence Synthesis Framework
For Single Trial
- Study design and population
- Intervention and comparator
- Primary endpoint results
- Key secondary endpoints
- Safety profile
- Limitations
- Clinical implications
For Multiple Trials
- Consistency of findings
- Magnitude of effect across studies
- Population differences
- Statistical heterogeneity
- Overall certainty assessment
- Synthesized recommendation
GRADE Assessment Process
Factors That Lower Certainty
- Risk of bias (unblinded, high dropout)
- Inconsistency (heterogeneous results)
- Indirectness (surrogate outcomes, different population)
- Imprecision (wide CIs, few events)
- Publication bias
Factors That Raise Certainty
- Large effect (RR >2 or <0.5)
- Dose-response gradient
- All plausible confounders would reduce effect
Output Formatting
Executive Summary (Always First)
- 3-5 key findings highlighted
- Primary recommendation
- Evidence grade
- Clinical bottom line
Recommendation Statement Format
We recommend [intervention] for [population] with [condition]
to [outcome] (GRADE 1B: strong recommendation, moderate certainty).
Supporting evidence: [Key trials with effect sizes]
Best Practices
- Specify patient population precisely
- Use standardized outcome definitions (RECIST, CTCAE, etc.)
- Report both relative and absolute effects
- Include number at risk for survival data
- Acknowledge funding sources of cited trials
- Note guideline concordance/discordance
- Address special populations (elderly, renal impairment, etc.)
NOT For
This skill is NOT for individual patient treatment decisions. For that, clinical judgment integrating patient preferences, comorbidities, and circumstances is required beyond evidence synthesis.
1---2name: clinical-decision-support3description: Clinical Decision Support4---5# Clinical Decision Support67Generate professional clinical decision support documents with GRADE evidence grading and statistical analysis for cardiology content.89## Triggers1011- User needs evidence-based treatment recommendations12- User is creating clinical guideline summaries13- User wants to analyze patient cohort data14- User needs to present evidence with GRADE grading15- User is developing clinical algorithms1617## Document Types1819### 1. Treatment Recommendation Reports2021**Structure**:221. Clinical question (PICO format)232. Evidence summary243. GRADE assessment254. Recommendation statement265. Implementation considerations2728**GRADE Evidence Levels**:29| Grade | Certainty | Meaning |30|-------|-----------|---------|31| 1A | High | Strong recommendation, high-quality evidence |32| 1B | Moderate | Strong recommendation, moderate evidence |33| 2A | High | Weak recommendation, high-quality evidence |34| 2B | Moderate | Weak recommendation, moderate evidence |35| 2C | Low | Weak recommendation, low-quality evidence |3637### 2. Patient Cohort Analysis3839**Components**:40- Demographics and baseline characteristics41- Biomarker stratification42- Outcome comparisons with statistics43- Subgroup analyses44- Clinical implications4546### 3. Guideline Summaries4748**Elements**:49- Recommendation class (I, IIa, IIb, III)50- Level of evidence (A, B, C)51- Key supporting trials52- Clinical context53- Special populations5455## Cardiology-Specific Applications5657### Heart Failure Management58- GDMT optimization pathways59- Device therapy eligibility60- Risk stratification (MAGGIC, Seattle HF Model)61- Stage-based recommendations6263### Coronary Artery Disease64- Revascularization decisions65- Medical therapy optimization66- Risk scores (SYNTAX, HEART, TIMI)67- Secondary prevention6869### Arrhythmia Management70- Anticoagulation decisions (CHA₂DS₂-VASc)71- Rate vs rhythm control72- Device therapy indications73- Ablation candidacy7475### Valvular Heart Disease76- Intervention timing77- Surgical vs transcatheter approach78- Risk assessment (STS, EuroSCORE)79- Surveillance recommendations8081## Statistical Presentation8283### Required Elements84- Hazard ratios with 95% CI85- Absolute risk differences86- Number needed to treat (NNT)87- P-values (exact, not just thresholds)88- Forest plots for multiple comparisons8990### Survival Analysis Display91- Kaplan-Meier curves92- Number at risk tables93- Median survival with CI94- Landmark analyses if appropriate9596## Evidence Synthesis Framework9798### For Single Trial991. Study design and population1002. Intervention and comparator1013. Primary endpoint results1024. Key secondary endpoints1035. Safety profile1046. Limitations1057. Clinical implications106107### For Multiple Trials1081. Consistency of findings1092. Magnitude of effect across studies1103. Population differences1114. Statistical heterogeneity1125. Overall certainty assessment1136. Synthesized recommendation114115## GRADE Assessment Process116117### Factors That Lower Certainty118- Risk of bias (unblinded, high dropout)119- Inconsistency (heterogeneous results)120- Indirectness (surrogate outcomes, different population)121- Imprecision (wide CIs, few events)122- Publication bias123124### Factors That Raise Certainty125- Large effect (RR >2 or <0.5)126- Dose-response gradient127- All plausible confounders would reduce effect128129## Output Formatting130131### Executive Summary (Always First)132- 3-5 key findings highlighted133- Primary recommendation134- Evidence grade135- Clinical bottom line136137### Recommendation Statement Format138```139We recommend [intervention] for [population] with [condition]140to [outcome] (GRADE 1B: strong recommendation, moderate certainty).141142Supporting evidence: [Key trials with effect sizes]143```144145## Best Practices1461471. **Specify patient population** precisely1482. **Use standardized outcome definitions** (RECIST, CTCAE, etc.)1493. **Report both relative and absolute effects**1504. **Include number at risk** for survival data1515. **Acknowledge funding sources** of cited trials1526. **Note guideline concordance/discordance**1537. **Address special populations** (elderly, renal impairment, etc.)154155## NOT For156157This skill is NOT for individual patient treatment decisions. For that, clinical judgment integrating patient preferences, comorbidities, and circumstances is required beyond evidence synthesis.